The purpose of this study was to prepare engineered particles of rivastigmine hydrogen tartrate 26 (RHT) and to characterize the physicochemical and aerodynamic properties, in comparison to a 27 lactose carrier formulation (LCF). Microparticles were prepared from ethanol/water solutions 28 containing RHT with and without the incorporation of L-leucine (Leu), using a spray dryer. Dry 29 powder inhaler formulations prepared were characterized by scanning electron microscopy, 30 powder X-ray diffraction, laser diffraction particle sizing, ATR-FTIR, differential scanning 31 calorimetry, bulk and tapped density, dynamic vapour sorption and in vitro aerosol deposition 32 behaviour using a next generation impactor. The smooth-surfaced spherical morphology of the 33 spray dried microparticles was altered by adding Leu, resulting in particles becoming 34 increasingly wrinkled with increasing Leu. Powders presented low densities. The glass 35 transition temperature was sufficiently high (>90ºC) to suggest good stability at room 36 temperature. As Leu content increased, spray dried powders presented lower residual solvent 37 content, lower particle size, higher fine particle fraction (FPF <5µm), and lower mass median 38
INTRODUCTION 61
(approximately 5 to 8 mg) and placed into 40 µL sealed aluminium pans with three vent holes 244 and scanned over a temperature range of 0-180 °C with a scanning rate of 5 °C/min. The DSC 245 system was controlled by Mettler Toledo STAR e software (version 6.10). The glass transition 246 temperature of RHT as supplied was determinate by the melt quench technique, through fast 247 heating the sample (20 °C/min) to 120 °C, and subsequently fast cooling (to 0ºC); the sample 248 was then scanned over a temperature range of 0 to 150 °C with a scanning rate of 5 °C/min. 249
Glass transition temperature for the formulations F and G (see Table 1 ) were obtained using a 250 modulated temperature DSC (MTDSC) and scans were taken by means of a DSC Q200 (TA 251
Instruments, United Kingdom) with a RCS90RP refrigerated cooling system (Curtin et under nitrogen purge and a heating rate of 10 °C/min was implemented in all measurements. 265
The TGA system was controlled by Mettler Toledo STARe software (version 6.10). The 266 residual solvent content (RSC) was defined as the weight loss in TGA between 25 and 100 °C, 267
and the values presented are the average of three analyses. 268 269
Attenuated Total Reflection-FTIR Spectroscopy (ATR-FTIR) 270 271
Infrared spectra were collected using a Perkin-Elmer Model Spectrum One FTIR 272 Spectrometer (USA) equipped with a UATR and a diamond/ZnSe crystal accessory as 273 previously described by Grossjohann et al. (2015) . Data were evaluated in Spectrum version 274 5.0.1 software. Each spectrum was acquired over the range from 650 to 4000 cm -1 with 275 resolution of 4 cm −1 and a minimum of six scans were collected to obtained an average good 276 quality spectra. A minimum of two analyses was performed for each sample. 277 278
Dynamic vapour sorption (DVS) 279
The water vapour sorption-desorption isotherms of lactose carrier-containing and carrier-281 free systems were obtained by means of an automated gravimetric vapour sorption analyser, 282 DVS Advantage-1 (Surface Measurements Systems Ltd, UK) as previously described (Amaro et 283 al., 2014) . Samples were equilibrated at 0% RH until a steady dry reference mass was recorded. 284
The samples were exposed to the following relative humidity (% RH) profile: 0% to 90% in 285 10% steps and the reverse for desorption at 25.0 ± 0.1⁰C. At each stage, the sample mass was 286 allowed to reach equilibrium, defined as dm/dt ≤ 0.002 mg/min over 10 min, before the RH was 287 changed. The amount of water uptake for each RH stage was expressed as a % of the dry sample 288 mass (m0) . A minimum of two analyses was performed for each sample. (Waters, USA). The analytical method used was based on the chromatographic conditions for 295 quantification of RHT raw material described in the United States Pharmacopoeia (USP, 2014). 296
Chromatographic separation was achieved isocratically at ambient temperature with a Kromasil 297 100A C8 column (4.6 x 150 mm; 5 μm). The mobile phase consisted of monobasic ammonium 298 phosphate buffer (8.6 mg/mL; pH 7.0), acetonitrile and methanol in 50:25:25 (v/v/v) ratio, and 299 was run at a flow rate of 1.2 mL/min. The eluent was monitored for 9 min at 215 nm with UV 300 detector for RHT determination, and, when applicable, the eluent was monitored for 4 min with 301 a fluorescence detector (excitation wavelength 490 nm; detection wavelength 530 nm). 302
Retention times were 5 min for RHT and 2 min for fluorescein. 303
The RHT content of each DPI formulation was quantified by HPLC and expressed as the 304 percentage of the initial amount. Each powder was measured in triplicate. 305 306 2.2.12 In vitro aerosol deposition studies using the Next Generation Impactor (NGI) 307
308
The pulmonary deposition of the spray dried powders and lactose carrier formulation was 309 estimated in vitro using a Next Generation Impactor (NGI, Copley Scientific Limited, 310
Nottingham, UK) operated under pharmacopoeial conditions (European Pharmacopeia, 2014) . 311
The flow rate was adjusted to achieve a pressure drop of 4 kPa in the powder inhaler 312 (Handihaler®, Boehringher Ingelheim, Ingelheim, Germany) and the time of aspiration was 313 adjusted to obtain 4 L air flow Tewes et al., 2010) . The pre-separator 314 was used in the deposition studies for the LCF formulation to remove coarse particles (lactose-315 carrier particles). NGI stages (stages 1 to 7 and filter) were coated with 1 mL of water. As 316 previously described by Amaro et al. (2011 Amaro et al. ( , 2014 , the dry powder inhaler was loaded with ano. 3 hard gelatin capsule loaded with 20 ± 2 mg of powder for each formulation test. After the 318 deposition on the NGI, the powder was collected from each individual stage (device, throat, 319 stages 1-7 and filter) and dissolved in a suitable volume of water prior to quantification by 320 HPLC using the method described in 2.2.11. The deposition profile of each formulation was 321 carried out in triplicate and the results presented are the average results of the replicated 322
analyses. 323
The emitted recovered dose (ED) was determined as the percent of total powder mass 324 exiting the capsule. The total amount of particles with aerodynamic diameters smaller than 5 325 and 3 µm was calculated by interpolation from the inverse of the standard normal cumulative 326 mass distribution less than stated size cut-off against the natural logarithm of the cut-off 327 diameter of the respective stages. This amount was considered as the fine particle fraction (FPF 328 %) below 5 µm and 3 µm, and expressed as a percentage of the ED. The mass median 329 aerodynamic diameter (MMAD) of the particles was determined from the same plot as the 330 particle size corresponding to the 50% point of the cumulative distribution, and the geometric 331
, where X is the particle size corresponding to the 332 84% point and size Y is the particle size corresponding 16% point of the cumulative distribution 333 Laser diffraction particle size analysis was employed to investigate the particle size 360 distribution of the spray dried powders ( Table 2 ). The particle size volume distribution, in all 361 cases, was narrow and monomodal with span values decreasing from 2.59 to 1.76 as the Leu 362 content increased. The median particle size (d50) decreased from 2.12 to 1.40μm as the 363 proportion of Leu increased from 5% to 20% w/w. A correlation between d50 and Leu 364 concentration was investigated and found to be significant (r 2 = 0.75, p = 0.02) -as the amount 365 of Leu increases the particle size decreases. 366
The bulk and tapped densities of spray dried formulations are presented in Table 2 . The 367 tapped density of the spray dried powders ranged between 0.18 and 0.50 g/cm 3 , although, only 368 the formulations containing 20% Leu exhibited a tapped density higher than 0.3 g/cm 3 . In 369 general, the increase of Leu concentration in the formulations slightly increased the tapped and 370 bulk densities. A linear relationship between density (bulk and tapped) and %Leu was observed 371 when the content of Leu increased to 20% w/w. 384 DSC scans (Fig. 3) showed a broad endotherm, probably due to residual solvent loss, 385 the glass transition, and thermal decomposition for both spray dried formulations and Inu as 386 supplied. A large broad endothermic peak present in the Inu as supplied, over the heating range 387 of 30 -100°C, was attributed to water loss, as confirmed by thermogravimetric analysis (Table  388 2). DSC scans were similar for all formulations, with a single glass transition step followed or 389 not by an exothermic peak (recrystallisation of the amorphous phase), that can be observed informulations C to G, and finally decomposition of the material. The Tg value of melt quenched 391
RHT was determined to be 38.24 ± 0.27°C and the Tg value of Inu as supplied was 156.02 ± 392 0.64°C. The Tg values of the spray dried formulations are listed in Table 2 , and indicate that the 393 presence of Leu significantly decreased (p = 0.0013) the Tg compared with the corresponding 394 spray dried formulation without Leu (formulation A). There was a correlation between the 395 amount of Leu (5 to 20% w/w) in the spray dried formulations (B to E) and the Tg (r 2 = 0.951). 396
An increase in RHT loading in the spray dried formulations from 7.5% to 15% RHT 397 (formulation F and G) did not appear to change the roughness of the particles (as viewed by 398 SEM, Fig. 1F and G compared to 1C and E). The d50 was less than 1.5 µm for the formulations 399 with higher RHT loading. However, the increase of RHT loading significantly reduced the Tg of 400 the spray dried formulation (F and G), which was expected due to the low Tg presented by the 401 drug (38.24 ± 0.27ºC). The residual solvent content (RSC) determined by TGA in the range of 402 25 -100 ºC for RHT, Leu and Inu as supplied was 0.55 ± 0.02%, 0.89 ± 0.07% and 6.18 ± 403 0.25%, respectively. As expected, Leu showed a low water content due to its hydrophobic 404
properties. The RSC of the spray dried formulations is shown in Table 2 . The statistical analysis 405
of RSC values revealed significant differences between formulations (p = 0.0045). 406
The ATR-FTIR spectrum of RHT as supplied was similar to that reported by Benkic et 407 In this study, a lactose carrier formulation (LCF) was developed and characterized in 426 order to compare the aerosolization properties with lactose carrier-free formulations. The LCFformulation consisted of a mixture of micronized RHT with carrier-lactose particles (Table 1) . 428
Through quantitative HPLC analysis (Table 2 ) we demonstrated that the LCF formulation 429 presented homogeneity of 98.02% with a RSD of 1.46%, indicating that the mixing time was 430 sufficient to promote the adhesion of RHT particles to the lactose carrier particles, resulting in 431 the formation of a homogeneous ordered mix. 432
The morphology of the LCF formulation and RHT as supplied after micronization are 433 shown in Fig. 1H and 1I, respectively; it was observed that micronized RHT particles adhered to 434 the coarse lactose particles. Table 2 (Fig. 7) . 467 468
Water vapour sorption and desorption isotherms of powders 469 470
Leu (as supplied) showed no vapour sorption (i.e. no increase in mass) with increase in 471 %RH (Fig. 8) , and no change in the crystallinity of the sample compared to the material as 472 supplied (Fig. 9) , which was expected due to the high hydrophobicity of the material (Gliński et The water vapour sorption and desorption isotherms for RHT were characterized by the 482
presence of an open hysteresis loop. The desorption isotherm showed a high initial mass loss 483 until ~30% RH followed by a constant mass loss and a final moisture uptake of approximately 484 4.3%. RHT is a very hygroscopic material; as RH increased so did the water uptake by RHT, 485 with solubilisation/deliquescence of the RHT at RH ≥ 70 %. The sample collected for PXRD 486 post DVS analysis was a glass-like material, which showed a loss of the original crystalline 487 pattern, to be replaced by what appeared to be an amorphous halo (Fig. 9) . However, it is likely 488 that the pattern reflects the deliquesced material and not a solid amorphous state. 489
Sorption and desorption isotherms for the lactose carrier-free formulations are shown in 490 indicating that water was entrapped in the system. The inflection point at 60% RH in all samples 496 was due to Inu crystallization, as evidenced by diffraction peaks in the PXRD, after DVS 497 analysis, that are characteristic of Inu (Fig. 9) . However, diffraction peaks related to Leu (6.2º 498 and 19.1º) were also identified. PXRD after DVS analysis revealed that all lactose carrier-free 499 formulations showed evidence of crystallinity. 500
The water vapour sorption and desorption isotherm for micronized RHT was similar to 501 that of the RHT as supplied (unmicronised material), for which high RH induced a high water 502 uptake (Fig. 11) , and PXRD analysis of the sample post DVS analysis again showed what 503 appeared to be an amorphous halo (Fig. 12) . Lactose monohydrate exhibits very low 504 hygroscopicity, as can be seen from the dynamic vapour sorption isotherms in Fig. 11 . Lactose 505 monohydrate exhibits only a low level of water adsorption (about 0.12% water at 90% RH) 506 indicative of surface adsorption on a crystalline structure, and the final moisture uptake 507
observed was approximately 0.02%. This may be explained by the fact that the crystalline 508 structure of the lactose as supplied already incorporates water molecules (~5% of water content 509
by Karl-Fisher, according to the supplier). 510
The water vapour sorption and desorption isotherms for the lactose carrier formulation 511 (LCF) are shown in Fig. 11 . The apparent solubilization of RHT at 60% RH was observed, 512 however, the LCF formulation retained crystalline characteristics after the DVS run, which is 513 attributed to the large proportion of the lactose monohydrate ingredient (92.5% w/w) present 514 (Fig. 12) . The LCF formulation absorbed about 4.2% water at 90% RH, and the final moisture 515 uptake observed (post the desorption phase) was approximately 0.1%. 516 517
In vitro aerosol deposition studies using the Next Generation Impactor (NGI) 518 519
The NGI deposition profiles and fine particle fractions of the spray dried formulations 520 and lactose carrier formulation are shown in Table 2 and represented in Fig. 13 . 521
DPI formulations presented favorable deposition characteristics that improved with 522
increasing Leu proportion, namely high emitted recovered dose (ED) between 85% and 93% 523 and minimal loss of drug in the capsule and device (Handihaler ® ) -less than 15% for all 524 formulations evaluated. In general, the formulations containing Leu produced higher FPF (< 5 525 µm and < 3 µm) compared to their counterpart formulation without Leu. The increase in Leu 526 from 5% to 20% w/w improved the FPF (< 3 µm) of the spray dried powders by almost two-527 fold. In contrast, the formulation spray dried without Leu (formulation A) and the LCF 528 (formulation H) demonstrated the lowest FPFs, FPF (< 5 µm) of 39% and 41% and FPF (< 3 529 µm) of 28% and 30%, respectively. A statistically significant difference (p < 0.05) was evident 530 between the FPF < 5 µm and FPF < 3 µm values measured for these samples. Likewise, the 531 formulation without Leu (formulation A) showed a profile with less deposition in stages with 532 cut off diameters less than 3 µm (after stage 2), while the spray dried powders combined with 533 different concentrations of Leu (formulation B to E) exhibited improved deposition profiles, due 534 to less deposition in the capsule, inhaler, mouth adapter and throat (MA/IP) and stage 1, in 535 comparison to a relatively higher deposition on stages 4 -7, with cut-off diameter < 2 µm. The 536 spray-dried formulations F (10% Leu) and G (20% Leu) which had a higher content of RHT(15.0% w / w) compared to RHT 7.5% (w/w) loading, showed the highest emitted recovered 538 dose (ED > 90%), high FPFs (between 57 -68%), and exhibited better deposition profile, with 539 relatively higher deposition on stages with cut-off diameters < 2 µm (4 to 7). 540 Table 2 observed that the addition of small amounts of trileucine in the formulations resulted in stable 561 dry powders with improved inhalation properties. In the current work, when Leu content was 562 increased in the formulations, a relatively narrow particle size distribution was observed, with a 563 corresponding decrease in span and d90 values ( Table 2 ), indicating that the powders were of an 564 appropriate size range to avoid deposition by inertial impaction in the oropharyngeal cavity 565 to 20% w/w) and/or an increase in the RHT loading (7.5 to 15% w/w) in the spray dried 568 formulations resulted in a reduction in the median particle size. 569
The presence of Leu clearly affected the particle morphology, as depicted in Fig. 1 observed by SE micrographs (Fig. A to G) ; where, the higher the proportion of Leu in the 585 formulation, the more wrinkled the surface and smaller the particle size became. Sou et al. 586
(2013) suggested that such changes in surface wrinkling/corrugation, resulting from Leu 587 addition, improves the dispersibility by reducing contact points between particles. In the current 588 work an improvement in dispersibility of the spray dried particles was demonstrated by the 589 better aerosolisation properties and deposition performance achieved with formulations B to G 590 that contain Leu, in comparison with the formulations without Leu (formulation A and LCF). 591
In general, particle bulk and tap density increased with increasing Leu content in the 592 formulation. These physical properties of powders are known to be affected by particle size, 593 particle shape, and interparticle contact. The inclusion of Leu in the formulation resulted in 594 significant reduction in particle size, hence more particles/powder could occupy a particular 595 volume than particles of larger size. In addition, particle shape and interparticle contact were 596 also modified. These particle properties led to particle packing modification: smaller particles 597 tend to pack more tightly with less interparticle voids; a corrugated shape can also pack more 598 tightly than a spherical shape and consequently result in particle mechanical interlocking with 599 less void space between particles. All these events tend to increase powder tap density, as more 600 particles/powder is packed into a smaller volume (Elversson and Fureby, 2005 ; Pilcer and 601
Amighi, 2010). 602
Inu is an amorphous oligosaccharide with high viscosity and is considered an inert 603 excipient and non-toxic. Inu was selected as a carrier material to formulate the DPI, in order to 604 increase the volume of powder loaded and delivered from the DPI device (Ní Ógáin et al., 605 2011). As a saccharide excipient, the Inu also functions to provide stability for amorphous 606 material during spray drying and on storage -due to its high glass transition temperature and 607 ability to replace hydrogen bond interactions as the water is removed during drying, thus 608 reducing molecular mobility and improving stability (Barclay et al., 2010; Hinrichs et al., 2001) . 609 Spray-dried Inu exhibits an amorphous structure by PXRD as seen in Fig. 2, confirmed  610 by the glass transition event shown in thermal analysis (Fig. 3) . The Inu was able to promote theglass stabilization of the API during the spray drying process of the formulations,in which the Table 2 . Outlet temperature, yield of spray dried powders, RHT loading, geometric particle size, bulk and tapped density, residual solvent content, glass transition and aerodynamic characteristics of lactose carrier-free spray dried formulations (A to G) and lactose carrier formulation (LCF).
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